What are the Challenges of Using Bispecific Antibodies?
Despite their promise, BsAbs face several challenges:
Manufacturing complexity: Producing BsAbs is more complex and costly compared to standard monoclonal antibodies. Potential toxicity: Dual targeting can sometimes lead to off-target effects and immune-related toxicities. Stability and half-life: Ensuring the stability and sufficient half-life of BsAbs in the bloodstream can be challenging.
